Navigation Links
Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
Date:5/15/2008

promotion with Baxter Healthcare Corporation. Mr. McRaith received his Bachelor of Science degree from the University of Iowa.

ABOUT HUMAN GENOME SCIENCES

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is on track to begin the delivery in fall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancer. HGS1029, a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins, is expected to enter Phase 1 clinical trials soon for the treatment of cancer. In addition, HGS has substantial financial rights to three products in the GlaxoSmithKline clinical development pipeline.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

SAFE HARBOR STATEMENT

This announcement contains forward-looking statements within the meaning of Secti
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
2. Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments
3. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
4. China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex
5. Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2008 Financial Results
6. Identity Sciences Introduces a New, Fast Forensic Human I.D. Test
7. Human Genome Sciences Advances Oncology Portfolio
8. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
9. Human Pheromone Sciences Announces Quarterly and Full Year Results
10. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
11. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... were treated with a statin in the hospital after ... to survive than those who were not, according to ... This study was conducted by the same researchers who ... improve survival in victims of ischemic stroke., Ischemic stroke ... blood vessel that blocks blood from reaching areas of ...
(Date:9/22/2014)... Research and Markets ( ... "Global Biotechnology Reagents Market 2014-2018" report ... Biotechnology reagents are chemical compounds or ... detect and examine another substance to provide a ... to prepare, collect, and examine specimens from the ...
(Date:9/22/2014)... (CTCs) in a mouse model of pancreatic cancer identified ... CTCs, including significant differences from the primary tumor that ... In their study reported in the Sept. 25 issue ... General Hospital (MGH) Cancer Center identified several different classes ... prove to be targets for improved treatment of the ...
(Date:9/22/2014)... Researchers have discovered a way to create a highly ... graphene sheets. The imperfections have unique electronic properties that ... to absorbed gas molecules by 300 times. , The ... Nature Communications . , Amin Salehi- Khojin, asst ... with Mohammad Asadi, graduate student and Bijandra Kumar, post ...
Breaking Biology Technology:Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Graphene imperfections key to creating hypersensitive 'electronic nose' 2
... of investigational sustained follicle stimulant achieves similar efficacy to ... week period in Phase III Study , , ... SGP ) today announced results from the Phase III ... corifollitropin alfa, first in the class of sustained follicle ...
... a subsidiary of Eisai Corporation of North America, announced ... express and develop therapeutic monoclonal antibodies for the potential ... , , Under the terms of the agreement, ... technology and its expertise to produce and develop a ...
... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that ... device and methods for linking biological agents to labels for ... as In-Line labeling, was developed for the production of radiolabeled ... A study published today in the July 2009 issue ...
Cached Biology Technology:Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 2Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 3Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 4Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 5Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 6Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 7Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 8Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa 9Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 2Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 2Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 4
(Date:9/22/2014)... the University of Chicago have shown that after a ... a handful of pathogenic microbe species remain behind in ... discovered that some can become deadly when provoked by ... , The findings, published in mBio , the ... may lead to better monitoring and treatment of ICU ...
(Date:9/22/2014)... --- Many native species have vanished from tropical ... Florida scientists have discovered how fossils can be ... key lies in organic materials found in fossil ... functioned, according to a new study available online ... Journal of Herpetology . Pre-human island ecosystems provide ...
(Date:9/22/2014)... of cut grass in recent years has been identified ... research says the aroma also summons beneficial insects to ... the plant signals the environment via the emission of ... queue for parasitic wasps to come to the plant ... pest insect," said Dr. Michael Kolomiets, Texas A&M AgriLife ...
Breaking Biology News(10 mins):Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Answer to restoring lost island biodiversity found in fossils 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3
... at St. Jude Children's Research Hospital have discovered how a ... effects ranging from learning and memory capabilities to glucose production ... called CREB, is a transcription factor—a molecule that binds to ... gene to make the specific protein for which it codes. ...
... provides the most compelling evidence to-date that some dinosaurs ... del Campo track site in Spain's Cameros Basin, contains ... a non-avian therapod dinosaur. , A team led ... La Rioja, Spain, discovered the prints in an area ...
... guys that help bacterial pathogens do their job of infecting ... essence, they knock down the front door of resistance and ... University of California, San Diego (UCSD) School of Medicine have ... YpkA, one of several effectors of the bacteria Yersinia – ...
Cached Biology News:St. Jude study shows genes play an unexpected role in their own activation 2Definitive evidence found of a swimming dinosaur 2How plague-causing bacteria disarm host defense 2
Request Info...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
Biology Products: